Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with Chemotherapy in Advanced Ovarian Cancer
NCT03275506Phase 2Completed
- Sponsor
- ARCAGY
- Start
- Feb 2018
- Primary completion
- Sep 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in ovarian cancer (2 arms), sponsored by ARCAGY. Primary endpoint: Complete Resection Rate at Interval Debulking Surgery. Started Feb 2018; status: completed.
02
Drugs
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03275506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03275506.